FindTrial
Sign In

Identification and clinical application of serum exocrine miRNA model in patients with CA125 negative high grade serous ovarian cancer

Identification and clinical application of serum exocrine miRNA model in patients with CA125 negative high grade serous ovarian cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037259
Enrollment
Unknown
Registered
2020-08-27
Start date
2022-01-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Gold Standard:Postoperative pathological diagnosis
Index test:Construction&#32
of&#32
Exocrine&#32
miRNA&#32
Model

Sponsors

Fudan university Shanghai cancer center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients in normal ovarian group, benign ovarian tumor group, early HGSOC group, late HGSOC group, and HGSOC chemotherapy sensitive group and chemoresistance group were at 1:1:1:1.

Exclusion criteria

Exclusion criteria: Pathological diagnosis of other types of ovarian cancer.

Design outcomes

Primary

MeasureTime frame
miRNA in exosome;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactLingfang Xia

Fudan University Shanghai Cancer Center

nightxlf@163.com+86 18017317878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026